Ventracor chalks up first revenues

By Ruth Beran
Tuesday, 20 September, 2005

Ventracor (ASX:VCR) has received its first revenues, in the form of a cheque from the University of Maryland Medical Centre as payment for a VentrAssist left ventricular assist device (LVAD) recently implanted in a patient as part of its US clinical trial.

The company previously indicated it would reach the milestone before the end of 2005.

Unhealthy Western diet could accelerate cognitive decline

An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Content from other channels on our network

The roles of the vendor and EPCs in the project bidding process

ARC awards $82.5m for new research hubs and training centres

Industrial electricity costs could halve by sharing infrastructure

Seeq and Applied Computing partner on industrial AI for energy operations

ARENA opens Round 3 of Solar Sunshot with $250m available

AFGC welcomes Domestic Gas Reservation Bill

Beverage facility built to keep the good times rolling

Industries transitioning away from gas, A2EP report released

Six on the shelf: from frozen treats to smoothies & meal kits

58% of food manufacturers report less productivity, research finds

Burnout in health care isn't an 80/20 problem: why a more balanced view is needed and what it means for you and your workplace

A Good Cleaning Schedule: Best Practices for Healthcare Facilities

Conviction and $20K fine follows "serious and prolonged" offending by former podiatrist

Supagas acquires Heeson Medical

Why digital resilience is becoming critical in aged care